Access the Medtronic ESGE webinar and hear from the experts about a new endoscopic hemostasis system for active bleeds and prevention of delayed bleeding after resection.
These instructions provide a step-by-step guide on how to setup and use the NexpowderTM* Endoscopic Hemostatic System.
Watch the Instructional Video or download the Procedural Guide.
A prospective study assessed the feasibility of NexPowder™* application in refractory upper gastrointestinal bleeding in 17 patients, and has shown:
In a retrospective study in Korea monotherapy with NexPowder™* was administered to 56 patients with active bleeding. Immediate haemostasis was achieved in 96.4% (54/56) with a re-bleeding rate of 3.7% (2/54) and no adverse events.2
Authors: Jongbeom Shin et al.
Published in: BMC Gastroenterol (2021) 21:40
Conclusion: In conclusion, this single-arm study demonstrated Nexpowder™ was associated with excellent immediate hemostasis rate and safety profile as well as low rebleeding for upper GI tumor bleeding.
In this video, Dr. Beyna discusses his experience with NexpowderTM* in two seperate cases, one in the lower GI and one in the upper GI area, and how NexpowderTM* can be applied in both active and non-active bleeding.
In this video Dr. Beyna, demonstates the assembly of the NexpowderTM* components and using the system on a bleeding site. Upon deployment, NexpowderTM* transforms into a highly adhesive gel that creates a mechanical barrier.
The Nexpowder™* endoscopic hemostasis system is a powder that can be sprayed to an ulcer site, applying an endoscopic hemostatic agent. As a hydrophilic biocompatible adhesive material, it is composed of succinic anhydride (ε-poly-(L-lysine)) and oxidized dextran.
The Nexpowder™* system forms the adhesive gel after making contact with the water or blood by reversible crosslinking. Crosslinked gel helps prevent bleeding, loss of body fluid and contamination of the ulcer site by adhering to the bleeding site in the gastrointestinal tract and then gel degrades within 1 day to 3 days.3,4,5
The Nexpowder™* endoscopic hemostasis system is used for most types of GI bleeding. The device is applied during an endoscopic procedure and can cover ulcer or bleeding sites. The device is not intended for use in patients with variceal bleeding.
Because the Nexpowder™* system includes lactose, it is contraindicated in patients who have galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption and they would be atrisk of having a nausea, bloating, and diarrhea. Because the Nexpowder™* system includes Brilliant Blue FCF, it must not be used in patients with known hypersensitivity to brilliant blue FCF.
Contact us to learn more about the clinical applications of Nexpowder™* Endoscopic Hemostasis System.
™* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company
1. Antunes C, Copelin II EL. Upper Gastrointestinal Bleeding. [Updated 2019 Sep 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470300/
2. Raphaeli T, Menon R. Current treatment of lower gastrointestinal hemorrhage. Clin Colon Rectal Surg. 2012;25(4):219-227. doi:10.1055/s-0032-1329393
3. Park JS, Kim HK, Shin YW, et al. Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding. Endosc Int Open. 2019 Dec; 7(12):E1763-E1767.
4. Park JS, Bang BW, Hong SJ, et al. Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding: a pilot study. Endoscopy. 2019 May; 51(5):458-462.
5. Bang B, Lee E, Maeng J, et al. Efficacy of a novel endoscopically deliverable muco-adhesive hemostatic powder in an acute gastric bleeding porcine model. PLoS One. 2019 Jun 11; 14(6):e0216829.